Thunen Shelley B has filed 65 insider transactions across 3 companies since March 2023.
Most recent transaction: a grant/award of 13500 shares of LENZ Therapeutics, Inc. ($LENZ) on June 11, 2025.
Activity breakdown: 0 open-market purchases and 26 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 11, 2025 | LENZ Therapeutics, Inc. | $LENZ | Thunen Shelley B | Director | A | Stock Option (right to buy) | 13500 | $0.00 | 13,500.0000 | 27,542,874 | 9999.99% | 0.05% |
| May 21, 2025 | AEON Biopharma, Inc. | $AEON | Thunen Shelley B | Not found | A | Restricted Stock Units | 308641 | $0.00 | 308,641.0000 | 3,984,876 | 9999.99% | 7.75% |
| April 14, 2025 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Common Stock | 7792 | $4.34 | 38,354.0000 | 40,490,542 | 25.50% | 0.02% |
| April 14, 2025 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Stock Option (right to buy) | 1387 | $0.00 | 0.0000 | 40,490,542 | 100.00% | 0.00% |
| April 14, 2025 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Stock Option (right to buy) | 6405 | $0.00 | 0.0000 | 40,490,542 | 100.00% | 0.02% |
| Feb. 27, 2025 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | A | Stock Option (right to buy) | 125000 | $0.00 | 125,000.0000 | 40,490,542 | 9999.99% | 0.31% |
| Oct. 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | S | Common Stock | 278 | $49.45 | 30,443.0000 | 0 | 0.90% | 0.00% |
| Oct. 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | S | Common Stock | 5201 | $47.96 | 40,242.0000 | 0 | 11.45% | 0.00% |
| Oct. 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | S | Common Stock | 9521 | $48.69 | 30,721.0000 | 0 | 23.66% | 0.00% |
| Oct. 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Stock option (right to buy) | 15000 | $0.00 | 83,367.0000 | 0 | 15.25% | 0.00% |
| Oct. 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Common Stock | 15000 | $16.00 | 45,443.0000 | 0 | 49.27% | 0.00% |
| Aug. 31, 2024 | AEON Biopharma, Inc. | $AEON | Thunen Shelley B | Director | A | Class A Common Stock | 36021 | $0.00 | 36,021.0000 | 539,840 | 9999.99% | 6.67% |
| Aug. 31, 2024 | AEON Biopharma, Inc. | $AEON | Thunen Shelley B | Director | A | Stock Option | 96210 | $0.00 | 96,210.0000 | 539,840 | 9999.99% | 17.82% |
| Aug. 7, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | A | Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 0 | 9999.99% | 0.00% |
| July 15, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Common Stock | 16505 | $4.34 | 30,443.0000 | 0 | 118.42% | 0.00% |
| July 15, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Stock Option (right to buy) | 5270 | $0.00 | 1,387.0000 | 0 | 79.16% | 0.00% |
| July 15, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | See remarks | M | Stock Option (right to buy) | 11235 | $0.00 | 6,405.0000 | 0 | 63.69% | 0.00% |
| July 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 6599 | $58.55 | 15,741.0000 | 0 | 29.54% | 0.00% |
| July 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 10000 | $0.00 | 36,805.0000 | 0 | 21.37% | 0.00% |
| July 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 10000 | $15.60 | 23,938.0000 | 0 | 71.75% | 0.00% |
| July 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 8146 | $58.41 | 15,792.0000 | 0 | 34.03% | 0.00% |
| July 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 1854 | $59.48 | 13,938.0000 | 0 | 11.74% | 0.00% |
| July 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 1803 | $59.56 | 13,938.0000 | 0 | 11.45% | 0.00% |
| May 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 9620 | $52.68 | 22,720.0000 | 0 | 29.75% | 0.00% |
| May 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 10000 | $0.00 | 46,805.0000 | 0 | 17.60% | 0.00% |
| May 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 10247 | $15.60 | 32,340.0000 | 0 | 46.38% | 0.00% |
| May 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 380 | $53.04 | 22,340.0000 | 0 | 1.67% | 0.00% |
| April 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 662 | $50.24 | 22,836.0000 | 0 | 2.82% | 0.00% |
| April 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 8857 | $49.81 | 33,236.0000 | 0 | 21.04% | 0.00% |
| April 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 800 | $50.27 | 32,436.0000 | 0 | 2.41% | 0.00% |
| April 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 8938 | $49.81 | 23,498.0000 | 0 | 27.56% | 0.00% |
| April 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 200 | $50.37 | 22,636.0000 | 0 | 0.88% | 0.00% |
| April 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 543 | $51.50 | 22,093.0000 | 0 | 2.40% | 0.00% |
| March 21, 2024 | LENZ Therapeutics, Inc. | $LENZ | Thunen Shelley B | Director | A | Stock Option (right to buy) | 27000 | $0.00 | 27,000.0000 | 0 | 9999.99% | 0.00% |
| March 19, 2024 | AEON Biopharma, Inc. | $AEON | Thunen Shelley B | Director | A | Stock Option | 16260 | $0.00 | 16,260.0000 | 516,404 | 9999.99% | 3.15% |
| March 4, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | A | Stock Option (right to buy) | 92200 | $0.00 | 92,200.0000 | 0 | 9999.99% | 0.00% |
| March 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 10000 | $15.60 | 52,093.0000 | 0 | 23.76% | 0.00% |
| March 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 1166 | $54.95 | 50,927.0000 | 0 | 2.24% | 0.00% |
| March 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 6361 | $56.38 | 44,566.0000 | 0 | 12.49% | 0.00% |
| March 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 2473 | $57.03 | 42,093.0000 | 0 | 5.55% | 0.00% |
| March 1, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 10000 | $0.00 | 56,805.0000 | 0 | 14.97% | 0.00% |
| Feb. 5, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 6900 | $4.34 | 42,093.0000 | 0 | 19.61% | 0.00% |
| Feb. 5, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 9125 | $14.95 | 51,218.0000 | 0 | 21.68% | 0.00% |
| Feb. 5, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 9125 | $47.02 | 13,691.0000 | 0 | 39.99% | 0.00% |
| Feb. 6, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 15875 | $14.95 | 57,968.0000 | 0 | 37.71% | 0.00% |
| Feb. 6, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 15875 | $47.47 | 42,093.0000 | 0 | 27.39% | 0.00% |
| Feb. 5, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 6900 | $0.00 | 17,640.0000 | 0 | 28.12% | 0.00% |
| Feb. 5, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 9125 | $0.00 | 110,875.0000 | 0 | 7.60% | 0.00% |
| Feb. 6, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 15875 | $0.00 | 95,000.0000 | 0 | 14.32% | 0.00% |
| Jan. 26, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 4500 | $4.34 | 35,193.0000 | 0 | 14.66% | 0.00% |
| Jan. 26, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 31772 | $15.08 | 66,965.0000 | 0 | 90.28% | 0.00% |
| Jan. 26, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 31772 | $47.11 | 35,193.0000 | 0 | 47.45% | 0.00% |
| Jan. 26, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 4500 | $0.00 | 24,540.0000 | 0 | 15.50% | 0.00% |
| Jan. 26, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 31772 | $0.00 | 16,629.0000 | 0 | 65.64% | 0.00% |
| Jan. 2, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 4519 | $38.77 | 36,174.0000 | 0 | 11.11% | 0.00% |
| Jan. 2, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 10000 | $15.60 | 40,693.0000 | 0 | 32.58% | 0.00% |
| Jan. 2, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 5481 | $39.63 | 30,693.0000 | 0 | 15.15% | 0.00% |
| Jan. 2, 2024 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 10000 | $0.00 | 66,805.0000 | 0 | 13.02% | 0.00% |
| Dec. 15, 2023 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 20000 | $39.35 | 30,693.0000 | 0 | 39.45% | 0.00% |
| Dec. 15, 2023 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Common Stock | 20000 | $15.60 | 50,693.0000 | 0 | 65.16% | 0.00% |
| Dec. 15, 2023 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 10000 | $39.32 | 30,693.0000 | 0 | 24.57% | 0.00% |
| Dec. 15, 2023 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | M | Stock Option (right to buy) | 20000 | $0.00 | 76,805.0000 | 0 | 20.66% | 0.00% |
| Dec. 15, 2023 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | S | Common Stock | 10000 | $39.31 | 40,693.0000 | 0 | 19.73% | 0.00% |
| Aug. 14, 2023 | AEON Biopharma, Inc. | $AEON | Thunen Shelley B | Director | A | Stock Option | 58851 | $0.00 | 58,851.0000 | 138,848,177 | 9999.99% | 0.04% |
| March 9, 2023 | RxSight, Inc. | $RXST | Thunen Shelley B | Chief Financial Officer | A | Stock Option (right to buy) | 120000 | $0.00 | 120,000.0000 | 0 | 9999.99% | 0.00% |